SCHEMBL4505627

SCHEMBL4505627

Cc1nc(-c2cccnc2)nc(-c2cccc([N+](=O)[O-])c2)c1C(=O)NCCCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.54
▸ HPGD P15428 2/20 0.54
▸ EPHX2 P34913 1/20 0.48
▸ CYP19A1 P11511 1/20 0.47
▸ CYP11B1 P15538 1/20 0.47
▸ CYP11B2 P19099 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ PTAFR P25105 4/20 0.45
▸ PDE5A O76074 2/20 0.45
▸ MAPT P10636 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ABCG2 Q9UNQ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4492831 0.92 ALDH1A1 (0.60) ALDH1A1HPGDSMN1; SMN2PKMNPC1
SCHEMBL4507646 0.88 PTAFR (0.57) ALDH1A1EPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL4509962 0.88 EPHX2 (0.58) ALDH1A1EPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL4509189 0.86 EPHX2 (0.51) EPHX2SMN1; SMN2NPC1RAB9APTAFR
SCHEMBL4507240 0.86 PTAFR (0.52) EPHX2SMN1; SMN2NPC1RAB9APTAFR
SCHEMBL4497574 0.86 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2PKMNPC1
SCHEMBL4512752 0.86 EPHX2 (0.58) ALDH1A1EPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL13955313 0.86 EPHX2 (0.50) EPHX2SMN1; SMN2NPC1RAB9APTAFR
SCHEMBL4507410 0.85 PTAFR (0.58) EPHX2PTAFRMAPTL3MBTL1
SCHEMBL4504537 0.84 EPHX2 (0.50) EPHX2NPC1RAB9APTAFRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7494989-B2 Pyridine compounds useful as N-type calcium channel antagonists AJINOMOTO CO., INC. (JP) 2009-02-24 — — US disclosed
US-7494989-B2 Pyridine compounds useful as N-type calcium channel antagonists AJINOMOTO CO., INC. (JP) 2009-02-24 — — US disclosed
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2008-03-20 — — US disclosed
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2008-03-20 — — US disclosed
US-7288544-B2 Pyrimidine compounds useful as N-type calcium channel antagonists AJINOMOTO CO., INC. (JP) 2007-10-30 — — US disclosed
US-7288544-B2 Pyrimidine compounds useful as N-type calcium channel antagonists AJINOMOTO CO., INC. (JP) 2007-10-30 — — US disclosed
US-7288544-B2 Pyrimidine compounds useful as N-type calcium channel antagonists AJINOMOTO CO., INC. (JP) 2007-10-30 — — US disclosed
US-20040009991-A1 Pyrimidine derivatives and new pyridine derivatives AJINOMOTO CO., INC. (JP) 2004-01-15 — — US disclosed
EP-1318147-A1 NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2003-06-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES P2RY10, CACNA1B, CACNA1E ALDH1A1 2263/4885HPGD 347/4885EPHX2 1239/4885
US-20040009991-A1 Pyrimidine derivatives and new pyridine derivatives CACNA1I, CACNA1B, CACNA1E ALDH1A1 840/4885HPGD 331/4885EPHX2 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback